0001628280-24-004287.txt : 20240212
0001628280-24-004287.hdr.sgml : 20240212
20240212172328
ACCESSION NUMBER: 0001628280-24-004287
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Taveras Arthur
CENTRAL INDEX KEY: 0001830901
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 24621370
MAIL ADDRESS:
STREET 1: C/O X4 PHARMACEUTICALS, INC.
STREET 2: 61 NORTH BEACON STREET, 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
wk-form4_1707776584.xml
FORM 4
X0508
4
2024-02-12
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001830901
Taveras Arthur
C/O X4 PHARMACEUTICALS, INC.
61 NORTH BEACON STREET 4TH FLOOR
BOSTON
MA
02134
0
1
0
0
Chief Scientific Officer
0
Common Stock
2024-02-12
4
S
0
787
1.0072
D
248536
D
Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023.
/s/ Adam S. Mostafa, attorney-in-fact
2024-02-12